(Q45868306)

17 December 2017

title

Experimental gene therapy of cancer using tumor cells engineered to secrete interleukin-13. (English)

1 reference

17 December 2017

0 references

Lebel-Binay S

1

1 reference

17 December 2017

Laguerre B

2

1 reference

17 December 2017

Quintin-Colonna F

3

1 reference

17 December 2017

Conjeaud H

4

1 reference

17 December 2017

Magazin M

5

1 reference

17 December 2017

Miloux B

6

1 reference

17 December 2017

Pecceu F

7

1 reference

17 December 2017

Caput D

8

1 reference

17 December 2017

Ferrara P

9

1 reference

17 December 2017

Fradelizi D

10

1 reference

17 December 2017

language of work or name

English

0 references

publication date

1 August 1995

1 reference

17 December 2017

European Journal of Immunology

published in

1 reference

17 December 2017

volume

25

1 reference

17 December 2017

page(s)

2340-2348

1 reference

17 December 2017

issue

8

1 reference

17 December 2017

Local administration of cells containing an inserted IL-2 gene and producing IL-2 inhibits growth of human tumours in nu/nu mice

cites work

1 reference

https://api.crossref.org/works/10.1002%2FEJI.1830250833

7 January 2021

Interleukin 2 gene transfer into tumor cells abrogates tumorigenicity and induces protective immunity

1 reference

https://api.crossref.org/works/10.1002%2FEJI.1830250833

7 January 2021

Interleukin-2 production by tumor cells bypasses T helper function in the generation of an antitumor response

1 reference

https://api.crossref.org/works/10.1002%2FEJI.1830250833

7 January 2021

Interleukin 2-dependent activation of tumor-specific cytotoxic T lymphocytes in vivo.

1 reference

https://api.crossref.org/works/10.1002%2FEJI.1830250833

7 January 2021

Inhibition of tumor growth by histoincompatible cells expressing interleukin-2

1 reference

https://api.crossref.org/works/10.1002%2FEJI.1830250833

7 January 2021

Mechanisms of rejection induced by tumor cell-targeted gene transfer of interleukin 2, interleukin 4, interleukin 7, tumor necrosis factor, or interferon gamma

1 reference

https://api.crossref.org/works/10.1002%2FEJI.1830250833

7 January 2021

Murine interleukin-4 displays potent anti-tumor activity in vivo

1 reference

https://api.crossref.org/works/10.1002%2FEJI.1830250833

7 January 2021

Treatment of established renal cancer by tumor cells engineered to secrete interleukin-4.

1 reference

https://api.crossref.org/works/10.1002%2FEJI.1830250833

7 January 2021

An eosinophil-dependent mechanism for the antitumor effect of interleukin-4

1 reference

https://api.crossref.org/works/10.1002%2FEJI.1830250833

7 January 2021

https://api.crossref.org/works/10.1002%2FEJI.1830250833

1 reference

7 January 2021

Interleukin-13 is a new human lymphokine regulating inflammatory and immune responses

1 reference

https://api.crossref.org/works/10.1002%2FEJI.1830250833

7 January 2021

TH1 and TH2 cells: different patterns of lymphokine secretion lead to different functional properties

1 reference

https://api.crossref.org/works/10.1002%2FEJI.1830250833

7 January 2021

Interleukin 13, a T-cell-derived cytokine that regulates human monocyte and B-cell function

1 reference

https://api.crossref.org/works/10.1002%2FEJI.1830250833

7 January 2021

Interleukin 13 induces interleukin 4-independent IgG4 and IgE synthesis and CD23 expression by human B cells.

1 reference

https://api.crossref.org/works/10.1002%2FEJI.1830250833

7 January 2021

Three-dimensional solution structure of human interleukin-4 by multidimensional heteronuclear magnetic resonance spectroscopy

1 reference

https://api.crossref.org/works/10.1002%2FEJI.1830250833

7 January 2021

The selective isolation of novel cDNAs encoded by the regions surrounding the human interleukin 4 and 5 genes

1 reference

https://api.crossref.org/works/10.1002%2FEJI.1830250833

7 January 2021

Receptors for interleukin-13 and interleukin-4 are complex and share a novel component that functions in signal transduction

1 reference

https://api.crossref.org/works/10.1002%2FEJI.1830250833

7 January 2021

Immunogenic variants obtained by mutagenesis of mouse mastocytoma P815. II. T lymphocyte-mediated cytolysis

1 reference

https://api.crossref.org/works/10.1002%2FEJI.1830250833

7 January 2021

„Natural”︁ killer cells in the mouse. I. Cytotoxic cells with specificity for mouse Moloney leukemia cells. Specificity and distribution according to genotype

1 reference

https://api.crossref.org/works/10.1002%2FEJI.1830250833

7 January 2021

Establishment of mouse cell lines which constitutively secrete large quantities of interleukin 2, 3, 4 or 5, using modified cDNA expression vectors

1 reference

https://api.crossref.org/works/10.1002%2FEJI.1830250833

7 January 2021

Receptor for interleukin 13. Interaction with interleukin 4 by a mechanism that does not involve the common gamma chain shared by receptors for interleukins 2, 4, 7, 9, and 15.

1 reference

https://api.crossref.org/works/10.1002%2FEJI.1830250833

7 January 2021

Role of bone marrow-derived cells in presenting MHC class I-restricted tumor antigens

1 reference

https://api.crossref.org/works/10.1002%2FEJI.1830250833

7 January 2021

Interleukin-13 alters the activation state of murine macrophages in vitro: comparison with interleukin-4 and interferon-gamma

1 reference

https://api.crossref.org/works/10.1002%2FEJI.1830250833

7 January 2021

Interleukin-13 stimulates interleukin-6 production by human keratinocytes. Similarity with interleukin-4.

1 reference

https://api.crossref.org/works/10.1002%2FEJI.1830250833

7 January 2021

Interleukin-4-mediated tumor suppression in nude mice involves interferon-gamma

1 reference

https://api.crossref.org/works/10.1002%2FEJI.1830250833

7 January 2021

Macrophage colony-stimulating factor gene transfer into tumor cells induces macrophage infiltration but not tumor suppression

1 reference

https://api.crossref.org/works/10.1002%2FEJI.1830250833

7 January 2021

Identifiers

DOI

10.1002/EJI.1830250833

1 reference

17 December 2017

PubMed ID

7664796

1 reference

17 December 2017